Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Distillate Capital Partners LLC

Distillate Capital Partners LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,317 shares of the company's stock after purchasing an additional 1,155 shares during the period. Distillate Capital Partners LLC owned about 0.14% of Medpace worth $14,723,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in MEDP. Pallas Capital Advisors LLC boosted its holdings in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after buying an additional 2,101 shares in the last quarter. Barclays PLC boosted its stake in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC grew its position in shares of Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after acquiring an additional 844 shares during the period. SYM FINANCIAL Corp purchased a new position in shares of Medpace in the 4th quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new position in Medpace in the 4th quarter worth about $9,335,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Down 0.1 %

Shares of Medpace stock traded down $0.22 on Thursday, hitting $296.28. 698,291 shares of the company were exchanged, compared to its average volume of 324,960. The company has a 50-day moving average price of $320.31 and a 200 day moving average price of $333.83. The stock has a market capitalization of $8.96 billion, a price-to-earnings ratio of 23.46, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 1-year low of $272.00 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on MEDP shares. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the stock from $370.00 to $328.00 in a report on Monday. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Mizuho cut their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $357.50.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.